Pacific Biosciences of California PACB Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Pacific Biosciences of California (PACB) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $263K in Q1 2026.
- How has Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 265.3% year-over-year, from $72K to $263K.
- What is the long-term trend for Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -94.1% compound annual growth rate (CAGR), from $4.78M to $1K.